Refill adherence and polypharmacy among patients with type 2 diabetes in general practice

Pharmacoepidemiology and Drug Safety

Volumn 18, Issue 11, 2009, Pages 983-991

  Van Bruggen, Rykel ^a   Gorter, Kees ^a   Stolk, Ronald P ^b   Zuithoff, Peter ^c   Klungel, Olaf H ^a   Rutten, Guy E H M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Patient adherence; Polypharmacy; Quality of care; Type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; GLUCOSE; HEMOGLOBIN A1C; HYPOCHOLESTEROLEMIC AGENT; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GENERAL PRACTICE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; PATIENT COMPLIANCE; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL;

AGED; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DRUG PRESCRIPTIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MEDICATION ADHERENCE; NETHERLANDS; POLYPHARMACY; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES;

EID: 70450213759     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1810     Document Type: Article

References (41)

1. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317(7160): 703-713.
2. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352(9131): 854-865.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837-853.
4. Colhoun HM, Betteridge DJ, Durrington PN, et al., Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364(9435): 685-696.
5. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361(9374): 2005-2016.
6. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New Engl J Med 2003; 348(5): 383-393. (Pubitemid 36159355)
7. American Diabetes Association. Standards of medical care in diabetes - 2006. Diabetes Care 2006; 29(Suppl 1): S4-42.
8. Bouma M, Rutten GE, de Grauw WJ, Wiersma T, Goudswaard AN. Summary of the practice guideline 'Diabetes mellitus type 2' (second revision) from the Dutch College of General Practitioners. Ned Tijdschr Geneeskd 2006; 150(41): 2251-2256.
9. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291(3): 335-342. (Pubitemid 38101606)
10. Grant RW, Buse JB, Meigs JB. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care 2005; 28(2): 337-442.
11. World Health Organization. Adherence to long-term therapies: evidence for action. Geneva. 2003.
12. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004; 27(5): 1218-1224. (Pubitemid 38579798)
13. Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care 2004; 27(9): 2149-2153.
14. Parris ES, Lawrence DB, Mohn LA, Long LB. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care 2005; 28(3): 595-599.
15. Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care 2004; 27(12): 2800-2805. (Pubitemid 39565040)
16. Schectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care 2002; 25(6): 1015-1021. (Pubitemid 41110487)
17. Bjerrum L, Sogaard J, Hallas J, Kragstrup J. Polypharmacy: correlations with sex, age and drug regimen. A prescription database study. Eur J Clin Pharmacol 1998; 54(3): 197-202.
18. Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care 2003; 26(5): 1408-1412. (Pubitemid 36929171)
19. Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002; 24(3): 460-467. (Pubitemid 34275867)
20. Vanderpoel DR, Hussein MA, Watson-Heidari T, Perry A. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydro-chloride in subjects with type 2 diabetes mellitus: a retrospective database analysis. Clin Ther 2004; 26(12): 2066-2075. (Pubitemid 40353616)
21. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. Clin Ther 2001; 23(8): 1311-1320. (Pubitemid 32804123)
22. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic patients. J Int Med Res 2002; 30(1): 71-79. (Pubitemid 34618725)
23. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med 2002; 19(4): 279-284.
24. van Bruggen R, Gorter KJ, Stolk RP, Verhoeven RP, Rutten GE. Implementation of locally adapted guidelines on type 2 diabetes. Fam Pract 2008; 8.
25. Rutten GEHM, Verhoeven S, Heine RJ, et al. Diabetes Mellitus Type 2. NHG-standaard (eerste herziening). Huisarts en Wetenschap 1999; 42: 67-84.
26. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35(11): 1095-1108. (Pubitemid 127453463)
27. Goddijn P, Bilo H, Meadows K, Groenier K, Feskens E, Meyboom-de Jong B. The validity and reliability of the Diabetes Health Profile (DHP) in NIDDM patients referred for insulin therapy. QualLife Res 1996; 5(4): 433-442. (Pubitemid 26292719)
28. Brooks R. EuroQol: the current state of play. Health Policy 1996; 37(1): 53-72.
29. Redekop WK, Koopmanschap MA, Stolk RP, Rutten GE, Wolffenbuttel BH, Niessen LW. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 2002; 25(3): 458-463. (Pubitemid 41103336)
30. Vik SA, Maxwell CJ, Hogan DB. Measurement, correlates, and health outcomes of medication adherence among seniors. Ann Pharmacother 2004; 38(2): 303-312.
31. Paes AH, Bakker A, Soe-Agnie CJ. Measurement of patient compliance. Pharm World Sci 1998; 20(2): 73-77.
32. Little RJA. Regression with missing X's: a review. J Am Stat Assoc 1992; 87: 1227-1237.
33. Winkler A, Teuscher AU, Mueller B, Diem P. Monotoring adherence to prescribed medication in type 2 diabetic patients treated with sulfonylureas. Swiss Med Wkly 2002; 132(27-28): 379-385. (Pubitemid 35285222)
34. Hertz RP, Unger AN, Lustik MB. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. Clin Ther 2005; 27(7): 1064-1073.
35. Lee R, Taira DA. Adherence to oral hypoglycemic agents in Hawaii. Prev Chronic Dis 2005; 2(2): A09.
36. Hsu J, Price M, Huang J, et al., Unintended consequences of caps on Medicare drug benefits. New Engl J Med 2006; 354(22): 2349-2359. (Pubitemid 43801280)
37. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004; 42(3): 200-209.
38. Hill-Briggs F, Gary TL, Bone LR, Hill MN, Levine DM, Brancati FL. Medication adherence and diabetes control in urban African Americans with type 2 diabetes. Health Psychol 2005; 24(4): 349-357. (Pubitemid 41099135)
39. Rhee MK, Slocum W, Ziemer DC, et al., Patient adherence improves glycemic control. Diabetes Educ 2005; 31(2): 240-250. (Pubitemid 40529013)
40. Hays RD, Kravitz RL, Mazel RM, et al. The impact of patient adherence on health outcomes for patients with chronic disease in the Medical Outcomes Study. J Behav Med 1994; 17(4): 347-360.
41. Donders AR, van der Heijden GJ, Stijnen T, Moons KG. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 2006; 59(10): 1087-1091. (Pubitemid 44374314)